Our Services
Medical Information
Helpful Resources
Published on: 9/26/2026
Women taking Wegovy (semaglutide) most often report nausea, vomiting, diarrhea, constipation, abdominal pain, heartburn, fatigue, headache, and injection site reactions, with many effects easing as the dose is gradually increased. Some women also notice changes in menstrual cycles, increased fertility and unplanned pregnancy as weight drops, hair thinning, gallbladder problems, and rapid facial or body fat loss. Rare but serious risks include pancreatitis, gallstones, kidney injury from dehydration, vision changes tied to diabetic retinopathy, gastroparesis, severe allergic reactions, and a boxed warning for thyroid C-cell tumors, and Wegovy should not be used during pregnancy or while breastfeeding. Risk varies based on dose, personal medical history, hormonal factors, and other medications, so there are several important details to weigh before starting or continuing treatment. See below to understand more about which symptoms are expected, which warrant urgent care, and how to reduce them.
If your symptoms feel more intense than expected, or you are unsure whether they come from Wegovy, a hormonal shift, or something unrelated, guessing can delay care you may need. A free, instant, online symptom check lets you describe what you are feeling in a few minutes and receive tailored insight into possible causes and how urgent they may be. That clarity helps you decide whether to adjust your routine, message your prescriber, or seek prompt medical attention, and it gives you clearer questions to bring to your next appointment.
Last reviewed for medical accuracy: 09/26/2026
Wegovy Side Effects in Females
Wegovy (semaglutide) is an FDA-approved prescription medication for chronic weight management in adults, including women with obesity or overweight plus weight-related conditions. Like all medicines, Wegovy can cause side effects. This guide focuses on wegovy side effects in females, drawing on credible sources such as the FDA label and peer-reviewed studies. It uses clear language, balanced information, and practical tips—without sugar-coating or inducing undue worry.
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics a natural gut hormone that:
By impacting appetite and calorie intake, Wegovy supports weight loss when combined with a reduced-calorie diet and regular exercise.
Most women tolerate Wegovy well, but many experience mild to moderate side effects—especially during the dose-escalation phase. Common wegovy side effects in females include:
These gastrointestinal (GI) effects tend to peak when the dose increases and often improve within a few weeks as your body adjusts.
GI symptoms are the most reported. Tips to manage them:
• Take Wegovy on the same day each week, with or without food.
• Eat smaller, more frequent meals.
• Choose low-fat, bland foods if you feel queasy.
• Stay hydrated—sip water throughout the day.
If severe vomiting or diarrhea leads to dehydration, electrolytes can drop quickly. In that case, seek medical advice.
Some women report:
These often appear early and fade over a few weeks. To cope:
• Get enough rest.
• Avoid sudden position changes if dizzy.
• Tell your doctor if headaches worsen or persist after two weeks.
Always inform your clinician about any intense upper-abdominal pain or new neck symptoms.
Rapid weight loss and GLP-1 therapy can increase gallstone risk. Women, especially those with obesity or rapid weight reduction, may experience:
Signs to watch for:
• Intense, steady pain in the right upper abdomen or back
• Fever and jaundice (yellowing of skin/eyes)
Report these symptoms promptly to avoid complications.
While rare, these side effects need immediate attention:
• Severe dehydration from persistent vomiting or diarrhea
• Acute kidney injury (signs: low urine output, swelling, fatigue)
• Hypoglycemia (low blood sugar), especially if you’re also on diabetes medications
• Allergic reactions (rash, itching, swelling, difficulty breathing)
If you experience any serious or troubling symptoms, stop Wegovy and seek medical care right away.
Use your best judgment and consider a free, online symptom check, using the doctor approved Ubie Symptom Checker for non-urgent questions or to decide if you need in-person care. If you experience any of the following, speak to a doctor or go to the emergency department:
Before starting Wegovy, disclose:
During treatment, keep your provider updated on:
Your doctor can adjust the dose, recommend supportive treatments, or switch therapies if needed.
Wegovy offers effective weight management for many women, but side effects are common, especially GI disturbances. Being informed and proactive helps you navigate these challenges:
If you ever wonder whether your symptoms warrant professional attention, try a free, online symptom check, using the doctor approved Ubie Symptom Checker. And remember: always speak to a doctor about any life-threatening or serious concerns—your health and safety come first.
(References)
* Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T, SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15. PMID: 27633186.
* Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.
* Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT, STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1403-1413. doi: 10.1001/jama.2021.1831. PMID: 33625476; PMCID: PMC7905697.
* Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K, SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647.
* Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Wharton S, STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022 Oct;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4. Epub 2022 Oct 10. PMID: 36216945; PMCID: PMC9556320.
* Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH, SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. PMID: 37952131.
* Karagiannis T, Malandris K, Avgerinos I, Stamati A, Kakotrichi P, Liakos A, Vasilakou D, Kakaletsis N, Tsapas A, Bekiari E. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. 2024 Jul;67(7):1206-1222. doi: 10.1007/s00125-024-06144-1. Epub 2024 Apr 13. PMID: 38613667; PMCID: PMC11153294.
* Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R, FLOW Trial Committees and Investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24. PMID: 38785209.
* Bliddal H, Bays H, Czernichow S, Uddén Hemmingsson J, Hjelmesæth J, Hoffmann Morville T, Koroleva A, Skov Neergaard J, Vélez Sánchez P, Wharton S, Wizert A, Kristensen LE, STEP 9 Study Group. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med. 2024 Oct 31;391(17):1573-1583. doi: 10.1056/NEJMoa2403664. PMID: 39476339.
* Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP, SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025 Jul 3;393(1):26-36. doi: 10.1056/NEJMoa2416394. Epub 2025 May 11. PMID: 40353578.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.